Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥2,157 JPY
Change Today -90.00 / -4.01%
Volume 2.6M
As of 2:00 AM 08/5/15 All times are local (Market data is delayed by at least 15 minutes).

mitsubishi tanabe pharma (4508) Snapshot

Open
¥2,147
Previous Close
¥2,247
Day High
¥2,178
Day Low
¥2,125
52 Week High
08/4/15 - ¥2,247
52 Week Low
08/8/14 - ¥1,504
Market Cap
1.2T
Average Volume 10 Days
1.5M
EPS TTM
¥79.86
Shares Outstanding
561.4M
EX-Date
09/28/15
P/E TM
27.0x
Dividend
¥44.00
Dividend Yield
1.95%
Current Stock Chart for MITSUBISHI TANABE PHARMA (4508)

Related News

No related news articles were found.

mitsubishi tanabe pharma (4508) Related Businessweek News

No Related Businessweek News Found

mitsubishi tanabe pharma (4508) Details

Mitsubishi Tanabe Pharma Corporation manufactures and sells pharmaceuticals in Japan and internationally. The company offers autoimmune drugs, including Remicade agent for rheumatoid arthritis and Crohn’s disease, Bechet’s disease with refractory uveoretinitis, psoriasis, ankylosing spondylitis, and ulcerative colitis; and Simponi agent for rheumatoid arthritis. It also provides drugs for diabetes and kidney diseases, such as Kremezin agent for chronic renal failure; and Tanatril agent for hypertension and diabetic nephropathy with type I diabetes mellitus, etc. In addition, the company offers drugs for central nervous system diseases comprising Radicut, a cerebral neuroprotectant; Ceredist agent for spinocerebellar degeneration; Depas, an anti-anxiety agent; and Lexapro, an anti-depressant agent. Further, it provides Maintate agent for treatment of hypertension, angina pectoris, ventricular extrasystole, chronic heart failure, and atrial fibrillation; Talion agent for allergic disorders; Urso agent for the improvement of hepatic, biliary, and digestive function; Anplag, an anti-platelet agent; and Herbesser, an agent for angina pectoris and hypertension. Additionally, the company offers vaccines, such as TETRABIK, a combined vaccine for diphtheria, pertussis, tetanus, and poliomyelitis; and influenza. It also provides over-the-counter products, including herbal and digestive medicines, as well as oral solutions for tonic and nutritional supplement; oral agent for allergic rhinitis; and products for the treatment of skin conditions and recurrent vaginal candidiasis. The company also offers pharmaceutical information and real estate management services; sells generic pharmaceuticals, chemicals, etc.; invests in bio-ventures; and is involved in distribution and warehouse operations. The company was founded in 1678 and is headquartered in Osaka, Japan. Mitsubishi Tanabe Pharma Corporation is a subsidiary of Mitsubishi Chemical Holdings Corporation.

8,457 Employees
Last Reported Date: 06/19/15
Founded in 1678

mitsubishi tanabe pharma (4508) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

mitsubishi tanabe pharma (4508) Key Developments

Mitsubishi Tanabe Pharma Corporation Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2015; Provides Consolidated Earnings Guidance for the First Half of Fiscal 2016 and Full Year Ending March 31, 2016

Mitsubishi Tanabe Pharma Corporation announced consolidated earnings results for the first quarter ended June 30, 2015. For the quarter, the company reported net sales of ¥98,487 million, operating income of ¥22,740 million, ordinary income of ¥22,642 million and net income attributable to shareholders of the company of ¥14,881 million or ¥26.53 per share compared to net sales of ¥94,559 million, operating income of ¥13,683 million, ordinary income of ¥14,562 million and net income attributable to shareholders of the company of ¥9,587 million or ¥17.09 per share for the same period a year ago. Net cash used in operating activities was ¥4,265 million against net cash provided by operating activities of ¥5,144 million a year ago period. Income before income taxes and non-controlling interests was ¥22,642 million against ¥14,890 million a year ago period. Purchase of property, plant and equipment was ¥2,377 million against ¥2,431 million a year ago period. Purchase of intangible fixed assets was ¥282 million against ¥505 million a year ago period. The company provided consolidated earnings guidance for the first half of fiscal 2016 and full year ending March 31, 2016. For the first half of fiscal 2016, the company expects net sales of ¥191,500 million, operating income of ¥28,000 million, ordinary income of ¥28,000 million and net income attributable to shareholders of the company of ¥19,000 million or ¥33.87 per share. For the full year ending March 31, 2016, the company expects net sales of ¥396,000 million, operating income of ¥67,500 million, ordinary income of ¥67,000 million and net income attributable to shareholders of the company of ¥40,500 million or ¥72.19 per share.

Mitsubishi Tanabe Pharma Corporation Provides Dividend Guidance for the Second Quarter and Fiscal Year 2015

Mitsubishi Tanabe Pharma Corporation provided dividend guidance of JPY 22.00 per share for the second quarter of fiscal year 2015. For the year, the company provided dividend guidance of JPY 22.00 per share for the fiscal year 2015.

Mitsubishi Tanabe Pharma Corporation, Q1 2016 Earnings Call, Jul 31, 2015

Mitsubishi Tanabe Pharma Corporation, Q1 2016 Earnings Call, Jul 31, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4508:JP ¥2,157.00 JPY -90.00

4508 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4508.
View Industry Companies
 

Industry Analysis

4508

Industry Average

Valuation 4508 Industry Range
Price/Earnings 27.8x
Price/Sales 3.0x
Price/Book 1.6x
Price/Cash Flow 21.7x
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MITSUBISHI TANABE PHARMA, please visit www.mt-pharma.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.